Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

Addiction

Volumn 112, Issue 7, 2017, Pages 1290-1299

  Gountas, Ilias ^a   Sypsa, Vana ^a   Anagnostou, Olga ^b   Martin, Natasha ^c,d   Vickerman, Peter ^d   Kafetzopoulos, Evangelos ^b   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Organization Against Drugs (OKANA)   (Greece)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antiviral therapy; dynamic modeling; elimination; Greece; harm reduction; hepatitis C; treatment as prevention

Indexed keywords

ANTIVIRUS AGENT;

CHRONIC HEPATITIS C; COMORBIDITY; GREECE; HARM REDUCTION; HUMAN; PREVALENCE; PRIMARY PREVENTION; PROCEDURES; SUBSTANCE ABUSE; THEORETICAL MODEL;

ANTIVIRAL AGENTS; COMORBIDITY; GREECE; HARM REDUCTION; HEPATITIS C, CHRONIC; HUMANS; MODELS, THEORETICAL; PREVALENCE; PRIMARY PREVENTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85013439710     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13764     Document Type: Article

References (52)

1. Hatzakis A., Van Damme P., Alcorn K., Gore C., Benazzouz M., Berkane S. et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepatol 2013; 20: 1–20.
2. Ly K. N., Xing J., Klevens R. M., Jiles R. B., Ward J. W., Holmberg S. D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–278.
3. Nelson P. K., Mathers B. M., Cowie B., Hagan H., Des Jarlais D., Horyniak D. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571–583.
4. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352–358.
5. Vickerman P., Hickman M., May M., Kretzschmar M., Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 2010; 105: 311–318.
6. Grebely J., Dore G. J. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral Res 2014; 104: 62–72.
7. Turner K. M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978–1988.
8. Vickerman P., Page K., Maher L., Hickman M., Commentary on Nolan et al. Opiate substitution treatment and hepatitis C virus prevention: building an evidence base? Addiction 2014; 109: 2060–2061.
9. Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984–1995.
10. Martin N. K., Vickerman P., Foster G. R., Hutchinson S. J., Goldberg D. J., Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137–1144.
11. Sulkowski M. S., Gardiner D. F., Rodriguez-Torres M., Reddy K. R., Hassanein T., Jacobson I. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–221.
12. Feld J. J., Kowdley K. V., Coakley E., Sigal S., Nelson D. R., Crawford D. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594–1603.
13. World Health Organization (WHO). Global Health Sector Strategy on Viral Hepatitis, 2016–2021. Geneva: WHO; 2015.
14. Martin N. K., Vickerman P., Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011; 274: 58–66.
15. Martin N. K., Vickerman P., Miners A., Foster G. R., Hutchinson S. J., Goldberg D. J. et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012; 55: 49–57.
16. Martin N. K., Vickerman P., Grebely J., Hellard M., Hutchinson S. J., Lima V. D. et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598–1609.
17. Martin N. K., Foster G. R., Vilar J., Ryder S., Cramp M. E., Gordon F. et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepatol 2015; 22: 399–408.
18. Hellard M. E., Jenkinson R., Higgs P., Stoove M. A., Sacks-Davis R., Gold J. et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196: 638–641.
19. Cousien A., Tran V. C., Deuffic-Burban S., Jauffret-Roustide M., Dhersin J. S., Yazdanpanah Y. Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 2016; 63: 1090–1101.
20. Martin N. K., Hickman M., Hutchinson S. J., Goldberg D. J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57: S39–S45.
21. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S–10S.
22. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561–573.
23. Dore G. J., Hellard M., Matthews G. V., Grebely J., Haber P. S., Petoumenos K. et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123–135. e1-2.
24. Backmund M., Meyer K., Von Zielonka M., Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188–193.
25. Reimer J., Schulte B., Castells X., Schafer I., Polywka S., Hedrich D. et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis 2005; 40: S373–8.
26. Foster G. R. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction 2008; 103: 1412–1413.
27. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40: S336–8.
28. Midgard H., Bjoro B., Maeland A., Konopski Z., Kileng H., Damas J. K. et al. Hepatitis C reinfection following sustained virological response—seven-year follow-up of patients infected through injecting drug use. J Hepatol 2016; 64: 1020–1026.
29. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–264.
30. European Association for Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199–236.
31. Sypsa V., Paraskevis D., Malliori M., Nikolopoulos G. K., Panopoulos A., Kantzanou M. et al. Homelessness and other risk factors for HIV infection in the current outbreak among injection drug users in Athens, Greece. Am J Public Health 2015; 105: 196–204.
32. Hatzakis A., Sypsa V., Paraskevis D., Nikolopoulos G., Tsiara C., Micha K. et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction 2015; 110: 1453–1467.
33. Paraskevis D., Nikolopoulos G., Tsiara C., Paraskeva D., Antoniadou A., Lazanas M. et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill 2011; 16: 19961.
34. National Centre of Documentation and Information on Drugs. Annual Report. 2014. Available at: http://www.ektepn.gr/Documents/PDF/Cover.pdf (accessed 13 February 2017) (Archived at http://www.webcitation.org/6oFBPWn9q).
35. Hatzakis A., Chulanov V., Gadano A. C., Bergin C., Ben-Ari Z., Mossong J. et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm, volume 2. J Viral Hepatol 2015; 22: 26–45.
36. Cousien A., Tran V. C., Deuffic-Burban S., Jauffret-Roustide M., Dhersin J. S., Yazdanpanah Y. Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review. J Viral Hepatol 2015; 22: 213–229.
37. Sypsa V., Touloumi G., Tassopoulos N. C., Ketikoglou I., Vafiadis I., Hatzis G. et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepatol 2004; 11: 366–374.
38. European Centre for Disease Prevention and Control (ECDC). Migrant Health: Access to HIV Prevention, Treatment and Care for Migrant Populations in EU/EEA Countries. Solna, Sweden: ECDC; 2009.
39. Mathers B. M., Degenhardt L., Bucello C., Lemon J., Wiessing L., Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013; 91: 102–123.
40. Dore G. J. The changing therapeutic landscape for hepatitis C. Med J Aust 2012; 196: 629–632.
41. Gane E. J., Stedman C. A., Hyland R. H., Ding X., Svarovskaia E., Symonds W. T. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34–44.
42. Poordad F., Lawitz E., Kowdley K. V., Cohen D. E., Podsadecki T., Siggelkow S. et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45–53.
43. Poordad F., McCone J. Jr., Bacon B. R., Bruno S., Manns M. P., Sulkowski M. S. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
44. Malliori M., Golna C., Souliotis K., Hatzakis A. Managing opioid dependence treatment and controlling for HIV incidence among injecting drug users in Greece: a case study of optimism in the face of adversity. Addiction 2013; 108: 1174–1175.
45. Page K., Hahn J. A., Evans J., Shiboski S., Lum P., Delwart E. et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216–1226.
46. Forton D. M. How much of a problem is resistance in treating hepatitis C? Curr Opin Infect Dis 2016; 29: 625–631.
47. Hellard M., McBryde E., Sacks D. R., Rolls D. A., Higgs P., Aitken C. et al. Hepatitis C transmission and treatment as prevention—the role of the injecting network. Int J Drug Policy 2015; 26: 958–962.
48. Shafran S. D. HIV co-infected have similar SVR rates as HCV monoinfected with DAAs: it's time to end segregation and integrate HIV patients into HCV trials. Clin Infect Dis 2015; 61: 1127–1134.
49. Valerio H., Goldberg D. J., Lewsey J., Weir A., Allen S., Aspinall E. J. et al. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: implications for reinfection. Drug Alcohol Depend 2015; 154: 125–131.
50. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: c5475.
51. Stoove M. A., Dietze P. M., Aitken C. K., Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008; 96: 281–285.
52. Jarrin I., Pantazis N., Gill M. J., Geskus R., Perez-Hoyos S., Meyer L. et al. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis 2012; 54: 111–118.